To investigate the protein alteration of the candidate signature biomarkers through cancer progression, the protein level of CALU, AURKA, and MCM2 was analyzed between 40 biopsy specimens and matched adjacent healthy tissues collected from CRC and lung cancer patients. The gene discussed is MCM2; the disease is colorectal carcinoma.